The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA DELIVERS RAPID AND SUSTAINED RELIEF FROM PRURITUS1*

Sustained reductions in pruritus up to 156 weeks1,a

Line graph showing sustained reductions in pruritus up to 156 weeks. Please read full Important Safety Information.

aESTEEM 1 study. Data as observed from patients in the full analysis set. Results were consistent between ESTEEM 1 and ESTEEM 2.

  • Among patients treated with OTEZLA 30 mg BID, improvements in pruritus VAS scores correlated with DLQI scores (rs = 0.55 [week 16]; rs ≥0.51 [week 32]; P < 0.001)2

OTEZLA significantly reduces pruritus severity as early as week 22

*Pruritus was measured on a 100-mm VAS. Baseline values: Placebo, 65.0 mm; OTEZLA 30 mg BID, 66.1 mm.

BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.

References:

  1. Data on file, Amgen Inc.
  2. Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514-520.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.